NFC-1 100 mg
MDGN-NFC1-ADHD-101
Phase 1 small_molecule completed
Quick answer
NFC-1 100 mg for Attention Deficit Disorder With Hyperactivity is a Phase 1 program (small_molecule) at Avalo Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Avalo Therapeutics
- Indication
- Attention Deficit Disorder With Hyperactivity
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed